1,066
Views
15
CrossRef citations to date
0
Altmetric
Comprehensive review

Unravelled facets of milk derived opioid peptides: a focus on gut physiology, fractures and obesity

ORCID Icon, , ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 36-49 | Received 18 Mar 2019, Accepted 30 Apr 2019, Published online: 03 Jun 2019

References

  • Abrahamson A. 2015. Galactose in dairy products [dissertation]. Uppsala, Sweden: Swedish University of Agricultural Sciences.
  • Alm L. 1982. Effect of fermentation on lactose, glucose, and galactose content in milk and suitability of fermented milk products for lactose intolerant individuals. J Dairy Sci. 65(3):346–352.
  • Andiran F, Dayi S, Mete E. 2003. Cows milk consumption in constipation and anal fissure in infants and young children. J Paediatr Child Health. 39(5):329–331.
  • Arnberg K, Mølgaard C, Michaelsen KF, Jensen SM, Trolle E, Larnkjaer A. 2012. Skim milk, whey, and casein increase body weight and whey and casein increase the plasma C-peptide concentration in overweight adolescents. J Nutr. 142(12):2083–2090.
  • Balzan S, de Almeida Quadros C, De Cleva R, Zilberstein B, Cecconello I. 2007. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol. 22(4):464–471.
  • Banerjee S, Sindberg G, Wang F, Meng J, Sharma U, Zhang L, Dauer P, Chen C, Dalluge J, Johnson T, et al. 2016. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol. 9(6):1418–1428.
  • Barba G, Troiano E, Russo P, Venezia A, Siani A. 2005. Inverse association between body mass and frequency of milk consumption in children. Br J Nutr. 93(1):15–19.
  • Barnes MJ, Holmes G, Primeaux SD, York DA, Bray GA. 2006. Increased expression of mu opioid receptors in animals susceptible to diet-induced obesity. Peptides. 27(12):3292–3298.
  • Barnett MP, McNabb WC, Roy NC, Woodford KB, Clarke AJ. 2014. Dietary A1 β-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 β-casein in Wistar rats. Int J Food Sci Nutr. 65(6):720–727.
  • Becker A, Hempel G, Grecksch G, Matthies H. 1990. Effects of beta-casomorphin derivatives on gastrointestinal transit in mice. Biomed Biochim Acta. 49(11):1203–1207.
  • Bell SJ, Grochoski GT, Clarke AJ. 2006. Health implications of milk containing beta-casein with the A2 genetic variant. Crit Rev Food Sci Nutr. 46(1):93–100.
  • Berin MC, Yang PC, Ciok L, Waserman S, Perdue MH. 1999. Role for IL-4 in macromolecular transport across human intestinal epithelium. Am J Physiol Cell Physiol. 276(5):C1046–C1052.
  • Bik EM, Ugalde JA, Cousins J, Goddard AD, Richman J, Apte ZS. 2018. Microbial biotransformations in the human distal gut. Br J Pharmacol. 175(24):4404–4414.
  • Boulange CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. 2016. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 8(1):42.
  • Boutrou R, Gaudichon C, Dupont D, Jardin J, Airinei G, Marsset-Baglieri A, Benamouzig R, Tome D, Leonil J. 2013. Sequential release of milk protein-derived bioactive peptides in the jejunum in healthy humans. Am J Clin Nutr. 97(6):1314–1323.
  • Brantl V, Teschemacher H, Blasig J, Henschen A, Lottspeich F. 1981. Opioid activities of β-casomorphins. Life Sci. 28(17):1903–1909.
  • Brantl V, Teschemacher H, Henschen A, Lottspeich F. 1979. Novel opioid peptides derived from casein (β-casomorphins). I. Isolation from bovine casein peptone. Hoppe-Seyler´ s Zeitschrift Physiol Chem. 360(2):1211–1224.
  • Cani PD, Delzenne NM. 2011. The gut microbiome as therapeutic target. Pharmacol Ther. 130(2):202–212.
  • Capaldo CT, Nusrat A. 2009. Cytokine regulation of tight junctions. Biochim BiophysActa (BBA) Biomembran. 1788(4):864–871.
  • Chakraborti CK. 2015. New-found link between microbiota and obesity. World J Gastrointest Pathophysiol. 6(4):110.
  • Chan LN. 2008. Opioid analgesics and the gastrointestinal tract. Pract Gastroenterol. 32:37–50.
  • Chen M, Pan A, Malik VS, Hu FB. 2012. Effects of dairy intake on body weight and fat: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 96(4):735–747.
  • Cieślińska A, Kostyra E, Kostyra H, Oleński K, Fiedorowicz E, Kamiński S. 2012. Milk from cows of different β-casein genotypes as a source of β-casomorphin-7. Int J Food Sci Nutr. 63(4):426–430.
  • Claustre J, Toumi F, Trompette A, Jourdan G, Guignard H, Chayvialle JA, Plaisancie P. 2002. Effects of peptides derived from dietary proteins on mucus secretion in rat jejunum. Am J Physiol Gastrointest Liver Physiol. 283(3):G521–G528.
  • Clayburgh DR, Shen L, Turner JR. 2004. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 84(3):282–291.
  • Colgan SP, Resnick MB, Parkos CA, Delp-Archer C, McGuirk D, Bacarra AE, Weller PF, Madara JL. 1994. IL-4 directly modulates function of a model human intestinal epithelium. J Immunol. 153(5):2122–2129.
  • Dahl K, Ahmed LA, Joakimsen RM, Jorgensen L, Eggen AE, Eriksen EF, Bjornerem A. 2015. High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: the Tromsø Study. Bone. 72:65–70.
  • Daniel H, Vohwinkel M, Rehner G. 1990. Effect of casein and beta-casomorphins on gastrointestinal motility in rats. J Nutr. 120(3):252–257.
  • De Noni I, Cattaneo S. 2010. Occurrence of β-casomorphins 5 and 7 in commercial dairy products and in their digests following in vitro simulated gastro-intestinal digestion. Food Chem. 119(2):560–566.
  • De Noni I, FitzGerald RJ, Korhonen HJ, Le Roux Y, Livesey CT, Thorsdottir I, Tome D, Witkamp R. 2009. Review of the potential health impact of β-casomorphins and related peptides. EFSA Sci Rep. 231:1–107.
  • Defilippi C, Gomez E, Charlin V, Silva C. 1995. Inhibition of small intestinal motility by casein: a role of beta casomorphins? Nutrition. 11(6):751–754.
  • Deth R, Clarke A, Ni J, Trivedi M. 2016. Clinical evaluation of glutathione concentrations after consumption of milk containing different subtypes of β-casein: results from a randomized, cross-over clinical trial. Nutr J. 15(1):82.
  • Elitsur Y, Luk G. 1991. Beta‐casomorphin (BCM) and human colonic lamina propria lymphocyte proliferation. Clin Exp Immunol. 85(3):493–497.
  • Elliott R, Harris D, Hill J, Bibby N, Wasmuth H. 1999. Type I (insulin-dependent) diabetes mellitus and cow milk: casein variant consumption. Diabetologia. 42(3):292–296.
  • Gadotti TN, Norde MM, Rogero MM, Fisberg M, Fisberg RM, Oki E, Martini LA. 2018. Dairy consumption and inflammatory profile: a cross-sectional population-based study, São Paulo, Brazil. Nutrition. 48:1–5.
  • Galligan JJ, Burks TF. 1983. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther. 226:356–361.
  • Garcia J, Khang-Loon H. 1996. Carotid atherosclerosis. Definition, pathogenesis, and clinical significance. Neuroimaging Clin N Am. 6(4):801–810.
  • Gill HS, Doull F, Rutherfurd K, Cross M. 2000. Immunoregulatory peptides in bovine milk. Br J Nutr. 84:111–117.
  • Gosnell B, Levine A. 2009. Reward systems and food intake: role of opioids. Int J Obes. 33(S2):S54.
  • Haq MRU, Kapila R, Saliganti V. 2014. Consumption of β-casomorphins-7/5 induce inflammatory immune response in mice gut through Th 2 pathway. J Funct Foods. 8:150–160.
  • Haq MRU, Kapila R, Shandilya UK, Kapila S. 2014. Impact of milk derived β-casomorphins on physiological functions and trends in research: a review. Int J Food Prop. 17:1726–1741.
  • Haq MRU, Kapila R, Sharma R, Saliganti V, Kapila S. 2014. Comparative evaluation of cow β-casein variants (A1/A2) consumption on Th2-mediated inflammatory response in mouse gut. Eur J Nutr. 53(4):1039–1049.
  • Hardy R, Cooper M. 2009. Bone loss in inflammatory disorders. J Endocrinol. 201(3):309–320.
  • He M, Sun J, Jiang ZQ, Yang YX. 2017. Effects of cow’s milk beta-casein variants on symptoms of milk intolerance in Chinese adults: a multicentre, randomised controlled study. Nutr J. 16:72.
  • Hilliard CB. 2016. High osteoporosis risk among East Africans linked to lactase persistence genotype. Bonekey Rep. 5:803.
  • Ho S, Woodford K, Kukuljan S, Pal S. 2014. Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study. Eur J Clin Nutr. 68(9):994–1000.
  • Hollander D. 1999. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep. 1(5):410–416.
  • Holzer P. 2009. Opioid receptors in the gastrointestinal tract. Regul Pept. 155(1–3):11–17.
  • Irastorza I, Ibanez B, Delgado-Sanzonetti L, Maruri N, Vitoria JC. 2010. Cow’s-milk-free diet as a therapeutic option in childhood chronic constipation. J Pediatr Gastroenterol Nutr. 51(2):171–176.
  • Iwan M, Jarmołowska B, Bielikowicz K, Kostyra E, Kostyra H, Kaczmarski M. 2008. Transport of micro-opioid receptor agonists and antagonist peptides across Caco-2 monolayer. Peptides. 29(6):1042–1047.
  • JanssenDuijghuijsen LM, Mensink M, Lenaerts K, Fiedorowicz E, van Dartel DAM, Mes JJ, Luiking YC, Keijer J, Wichers HJ, Witkamp RF, et al. 2016. The effect of endurance exercise on intestinal integrity in well‐trained healthy men. Physiol Rep. 4(20):e12994.
  • Jaruvongvanich V, Patcharatrakul T, Gonlachanvit S. 2017. Prediction of delayed colonic transit using Bristol stool form and stool frequency in eastern constipated patients: a difference from the west. J Neurogastroenterol Motil. 23(4):561.
  • Jianqin S, Leiming X, Lu X, Yelland GW, Ni J, Clarke AJ. 2016. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk. Nutr J. 15:35.
  • Jinsmaa Y, Yoshikawa M. 1999. Enzymatic release of neocasomorphin and β-casomorphin from bovine β-casein. Peptides. 20(8):957–962.
  • Kamiński S, Cieslińska A, Kostyra E. 2007. Polymorphism of bovine beta-casein and its potential effect on human health. J Appl Genet. 48(3):189–198.
  • Kashyap PC, Marcobal A, Ursell LK, Larauche M, Duboc H, Earle KA, Sonnenburg ED, Ferreyra JA, Higginbottom SK, Million M, et al. 2013. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology. 144(5):967–977.
  • Kost NV, Sokolov оY, Kurasova оB, Dmitriev AD, Tarakanova JN, Gabaeva МV, Zolotarev YA, Dadayan аK, Grachev SA, Korneeva еV, et al. 2009. β-Casomorphins-7 in infants on different type of feeding and different levels of psychomotor development. Peptides. 30(10):1854–1860.
  • Kraehenbuhl JP, Pringault E, Neutra M. 1997. Intestinal epithelia and barrier functions. Aliment Pharmacol Ther. 11:3–9.
  • Kundu P, Blacher E, Elinav E, Pettersson S. 2017. Our gut microbiome: the evolving inner self. Cell. 171(7):1481–1493.
  • Kurz A, Sessler DI. 2003. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 63(7):649–671.
  • Labonte ME, Cyr A, Abdullah MM, Lepine MC, Vohl MC, Jones P, Couture P, Lamarche B. 2014. Dairy product consumption has no impact on biomarkers of inflammation among men and women with low-grade systemic inflammation–3. J Nutr. 144:1760–1767.
  • Laugesen M, Elliott R. 2003. Ischaemic heart disease, type 1 diabetes, and cow milk A1 β-casein. N Z Med J. 116(1168):U295.
  • Lenard NR, Zheng H, Berthoud HR. 2010. Chronic suppression of μ-opioid receptor signaling in the nucleus accumbens attenuates development of diet-induced obesity in rats. Int J Obes. 34(6):1001.
  • Lewis S, Heaton K. 1997. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 32(9):920–924.
  • Linares DM, Ross P, Stanton C. 2016. Beneficial microbes: the pharmacy in the gut. Bioengineered. 7(1):11–20.
  • Macfarlane GT, Macfarlane S. 2012. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int. 95(1):50–60.
  • Makishima M. 2005. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci. 97(2):177–183.
  • Marczak ED, Jinsmaa Y, Myers PH, Blankenship T, Wilson R, Balboni G, Salvadori S, Lazarus LH. 2009. Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent µ-/δ-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol. 616(1–3):115–121.
  • Marques-Vidal P, Goncalves A, Dias C. 2006. Milk intake is inversely related to obesity in men and in young women: data from the Portuguese health interview survey 1998–1999. Int J Obes. 30(1):88–93.
  • Mattia C, Di Bussolo E, Coluzzi F. 2012. Non-analgesic effects of opioids: the interaction of opioids with bone and joints. Curr Pharm Des. 18(37):6005–6009.
  • McLachlan CN. 2001. beta-casein A1, ischaemic heart disease mortality, and other illnesses. Med Hypotheses. 56(2):262–272.
  • Meisel H. 1998. Overview on milk protein-derived peptides. Int Dairy J. 8(5–6):363–373.
  • Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R, Barke RA, Roy S. 2013. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS One. 8(1):e54040.
  • Michaelsson K, Wolk A, Langenskiold S, Basu S, Lemming EW, Melhus H, Byberg L. 2014. Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ. 349:g6015.
  • Moller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J. 2008. Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr. 47(4):171–182.
  • Nguyen DD, Johnson SK, Busetti F, Solah VA. 2015. Formation and degradation of beta-casomorphins in dairy processing. Crit Rev Food Sci Nutr. 55(14):1955–1967.
  • Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, Visser MR, Verhoef J, Gooszen HG, Akkermans L. 1998. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 228(2):188.
  • Ninkovic J, Roy S. 2013. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 45(1):9–24.
  • Overturf M, Smith S, Gotto A, Morrisett J, Tewson T, Poorman J, Loose-Mitchell D. 1990. Dietary cholesterol absorption, and sterol and bile acid excretion in hypercholesterolemia-resistant white rabbits. J Lipid Res. 31(11):2019–2027.
  • Pal S, Woodford K, Kukuljan S, Ho S. 2015. Milk intolerance, beta-casein and lactose. Nutrients. 7(9):7285–7297.
  • Pasco JA, Kotowicz MA, Henry MJ, Nicholson GC, Spilsbury HJ, Box JD, Schneider HG. 2006. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA. 296(11):1349–1355.
  • Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. 2002. Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch Intern Med. 162(5):537–540.
  • Patten GS, Head RJ, Abeywardena MY. 2011. Effects of casoxin 4 on morphine inhibition of small animal intestinal contractility and gut transit in the mouse. Clin Exp Gastroenterol. 4:23.
  • Perez-Castrillon JL, Olmos JM, Gomez JJ, Barrallo A, Riancho JA, Perera L, Valero C, Amado JA, Gonzalez MJ. 2000. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology. 72(3):187–194.
  • Rao R. 2009. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology. 50(2):638–644.
  • Rosen H, Krichevsky A, Bar‐Shavit Z. 1998. The enkephalinergic osteoblast. J Bone Miner Res. 13(10):1515–1520.
  • Roy S, Wang J, Charboneau R, Loh HH, Barke RA. 2005. Morphine induces CD4+ T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway. J Immunol. 175(10):6361–6367.
  • Runkel NS, Moody FG, Smith GS, Rodriguez LF, Chen Y, Larocco MT, Miller TA. 1993. Alterations in rat intestinal transit by morphine promote bacterial translocation. Dig Dis Sci. 38(8):1530–1536.
  • Schulte C. 2004. Bone disease in inflammatory bowel disease. Aliment Pharmacol Ther. 20(4):43–49.
  • Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M. 2009. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 1165:294–300.
  • Sienkiewicz-Szlapka E, Jarmołowska B, Krawczuk S, Kostyra E, Kostyra H, Bielikowicz K. 2009. Transport of bovine milk-derived opioid peptides across a Caco-2 monolayer. Int Dairy J. 19:252–257.
  • Singh M, Rosen CL, Chang KJ, Haddad GG. 1989. Plasma β-casomorphin-7 immunoreactive peptide increases after milk intake in newborn but not in adult dogs. Pediatr Res. 26(1):34.
  • Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. 2011. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci. 56(7):2088–2097.
  • Stefanucci A, Mollica A, Macedonio G, Zengin G, Ahmed AA, Novellino E. 2018. Exogenous opioid peptides derived from food proteins and their possible uses as dietary supplements: a critical review. Food Rev Int. 34(1):70–86.
  • Steinerova A, Stozicky F, Racek J, Tatzber F, Zima T, Setina R. 2001. Antibodies against oxidized LDL in infants. Clin Chem. 47(6):1137–1138.
  • Stephen AM, Wiggins HS, Cummings JH. 1987. Effect of changing transit time on colonic microbial metabolism in man. Gut. 28(5):601–609.
  • Sun Z, Cade R. 2003. Findings in normal rats following administration of gliadorphin-7 (GD-7). Peptides. 24(2):321–323.
  • Sun Z, Cade JR, Fregly MJ, Privette RM. 1999. β-Casomorphin induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism. 3:67–83.
  • Sun Z, Zhang Z, Wang X, Cade R, Elmir Z, Fregly M. 2003. Relation of β-casomorphin to apnea in sudden infant death syndrome. Peptides. 24(6):937–943.
  • Tailford KA, Berry CL, Thomas AC, Campbell JH. 2003. A casein variant in cow’s milk is atherogenic. Atherosclerosis. 170(1):13–19.
  • Takano T. 2002. Anti-hypertensive activity of fermented dairy products containing biogenic peptides. Antonie Van Leeuwenhoek. 82(1–4):333–340.
  • Tedelind S, Westberg F, Kjerrulf M, Vidal A. 2007. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 13(20):2826.
  • Torreilles J, Guerin MC. 1995. Casein-derived peptides can promote human LDL oxidation by a peroxidase-dependent and metal-independent process. C R Seances Soc Biol Fil. 189(5):933–942.
  • Tremaroli V, Backhed F. 2012. Functional interactions between the gut microbiota and host metabolism. Nature. 489(7415):242.
  • Trivedi MS, Hodgson NW, Walker SJ, Trooskens G, Nair V, Deth RC. 2015. Epigenetic effects of casein-derived opioid peptides in SH-SY5Y human neuroblastoma cells. Nutr Metab (Lond). 12:54.
  • Trompette A, Claustre J, Caillon F, Jourdan G, Chayvialle JA, Plaisancie P. 2003. Milk bioactive peptides and beta-casomorphins induce mucus release in rat jejunum. J Nutr. 133(11):3499–3503.
  • Tsuchita H, Sekiguchi I, Kuwata T, Igarashi C, Ezawa I. 1993. The effect of casein phosphopeptides on calcium utilization in young ovariectomized rats. Z Ernahrungswiss. 32(2):121–130.
  • Turner JR. 2009. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 9(11):799–809.
  • Ursell LK, Metcalf JL, Parfrey LW, Knight R. 2012. Defining the human microbiome. Nutr Rev. 70:S38–S44.
  • Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. 2011. Regulation of inflammation by short chain fatty acids. Nutrients. 3(10):858–876.
  • Wang F, Meng J, Zhang L, Johnson T, Chen C, Roy S. 2018. Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. Sci Rep. 8:3596.
  • Wasilewska J, Kaczmarski M, Kostyra E, Iwan M. 2011. Cow’s-milk–induced infant apnoea with increased serum content of bovine β-casomorphin-5. J Pediatr Gastroenterol Nutr. 52(6):772–775.
  • Wong JM, De Souza R, Kendall CW, Emam A, Jenkins DJ. 2006. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 40(3):235–243.
  • Xue B, Greenberg AG, Kraemer FB, Zemel MB. 2001. Mechanism of intracellular calcium ([Ca2+]i) inhibition of lipolysis in human adipocytes. Faseb J. 15(13):2527–2529.
  • Yuhan R, Koutsouris A, Savkovic SD, Hecht G. 1997. Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology. 113(6):1873–1882.
  • Zemel MB. 2002. Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr. 21(2):146S–151S.
  • Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. 2000. Regulation of adiposity by dietary calcium. Faseb J. 14(9):1132–1138.
  • Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, et al. 2013. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry. 18(12):1287.
  • Zoghbi S, Trompette A, Claustre J, El Homsi M, Garzón J, Jourdan G, Scoazec JY, Plaisancie P. 2006. β-Casomorphin-7 regulates the secretion and expression of gastrointestinal mucins through a μ-opioid pathway. Am J Physiol Gastrointest Liver Physiol. 290(6):G1105–G1113.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.